EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma

ConclusionEGFR gene amplification and classical subtype by TCGA analysis are associated with significantly shorter time to progression for patients with recurrent GBM when treated with bevacizumab. These findings can have a significant impact on decision-making and should be further validated prospectively.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research